MX2007001253A - Esquema de sintesis mejorado para lacosamida. - Google Patents

Esquema de sintesis mejorado para lacosamida.

Info

Publication number: MX2007001253A
Authority: MX; Mexico
Prior art keywords: compound; formula; lacosamide; benzyl; methoxypropionamide
Prior art date: 2004-10-02

Application number

MX2007001253A

Other languages

English (en)

Spanish (es)

Inventor

Jens Riedner

Gavin Dunne

Original Assignee

Sanol Arznei Schwarz Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-02

Filing date

2005-09-30

Publication date

2008-10-02

2005-09-30 Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh

2008-10-02 Publication of MX2007001253A publication Critical patent/MX2007001253A/es

Links

VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 title claims abstract description 43
229960002623 lacosamide Drugs 0.000 title claims abstract description 34
230000015572 biosynthetic process Effects 0.000 title description 18
238000003786 synthesis reaction Methods 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 61
238000000034 method Methods 0.000 claims abstract description 50
238000007069 methylation reaction Methods 0.000 claims abstract description 39
238000006243 chemical reaction Methods 0.000 claims abstract description 19
125000004432 carbon atom Chemical group C* 0.000 claims description 30
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
-1 hexafluoroantimonate Chemical group 0.000 claims description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 17
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 17
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 16
125000000217 alkyl group Chemical group 0.000 claims description 14
125000003118 aryl group Chemical group 0.000 claims description 14
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 13
229910052757 nitrogen Inorganic materials 0.000 claims description 13
239000003444 phase transfer catalyst Substances 0.000 claims description 12
239000012071 phase Substances 0.000 claims description 11
125000006239 protecting group Chemical group 0.000 claims description 11
WPLANNRKFDHEKD-SNVBAGLBSA-N Descarbonyl-lacosamide Chemical compound COC[C@@H](N)C(=O)NCC1=CC=CC=C1 WPLANNRKFDHEKD-SNVBAGLBSA-N 0.000 claims description 10
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 10
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 10
239000012022 methylating agents‎ Substances 0.000 claims description 10
150000002900 organolithium compounds Chemical class 0.000 claims description 10
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 9
125000003710 aryl alkyl group Chemical group 0.000 claims description 8
238000003408 phase transfer catalysis Methods 0.000 claims description 8
FHOAKXBXYSJBGX-RXMQYKEDSA-N (2r)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](CO)C(O)=O FHOAKXBXYSJBGX-RXMQYKEDSA-N 0.000 claims description 7
229930195711 D-Serine Natural products 0.000 claims description 7
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical group CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 7
238000006640 acetylation reaction Methods 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
239000011541 reaction mixture Substances 0.000 claims description 7
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Chemical group 0.000 claims description 6
239000008346 aqueous phase Substances 0.000 claims description 6
238000005580 one pot reaction Methods 0.000 claims description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 5
150000004820 halides Chemical group 0.000 claims description 5
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
238000006276 transfer reaction Methods 0.000 claims description 4
WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 claims description 4
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
239000012190 activator Substances 0.000 claims description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
239000012074 organic phase Substances 0.000 claims description 3
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 2
150000001718 carbodiimides Chemical class 0.000 claims description 2
238000002425 crystallisation Methods 0.000 claims description 2
230000008025 crystallization Effects 0.000 claims description 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical group OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims description 2
229910052698 phosphorus Inorganic materials 0.000 claims description 2
239000011574 phosphorus Substances 0.000 claims description 2
235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
239000011736 potassium bicarbonate Substances 0.000 claims description 2
229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
235000011181 potassium carbonates Nutrition 0.000 claims description 2
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
230000001681 protective effect Effects 0.000 claims description 2
229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical group [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
125000003944 tolyl group Chemical group 0.000 claims description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 3
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims 2
FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims 2
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 1
229910052500 inorganic mineral Inorganic materials 0.000 claims 1
239000011707 mineral Substances 0.000 claims 1
235000010755 mineral Nutrition 0.000 claims 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 16
239000000243 solution Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 12
230000011987 methylation Effects 0.000 description 10
125000005842 heteroatom Chemical group 0.000 description 9
150000002902 organometallic compounds Chemical class 0.000 description 9
229910052717 sulfur Inorganic materials 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
230000006340 racemization Effects 0.000 description 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
239000007787 solid Substances 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 5
239000012535 impurity Substances 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
150000004702 methyl esters Chemical class 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
150000008550 L-serines Chemical class 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
239000010410 layer Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000002904 solvent Substances 0.000 description 3
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 3
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000010533 azeotropic distillation Methods 0.000 description 2
HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
125000000753 cycloalkyl group Chemical group 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
238000002955 isolation Methods 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 1
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
QKFFSWPNFCXGIQ-UHFFFAOYSA-M 4-methylbenzenesulfonate;tetraethylazanium Chemical compound CC[N+](CC)(CC)CC.CC1=CC=C(S([O-])(=O)=O)C=C1 QKFFSWPNFCXGIQ-UHFFFAOYSA-M 0.000 description 1
YPKPTHXJBFTURD-FKXFFHFRSA-N C(C)(=O)N[C@@H](C(=O)NCC1=CC=CC=C1)COC.N[C@@H](C(=O)NCC1=CC=CC=C1)COC Chemical compound C(C)(=O)N[C@@H](C(=O)NCC1=CC=CC=C1)COC.N[C@@H](C(=O)NCC1=CC=CC=C1)COC YPKPTHXJBFTURD-FKXFFHFRSA-N 0.000 description 1
DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
150000008569 D-serines Chemical class 0.000 description 1
241000272184 Falconiformes Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
VJGNLOIQCWLBJR-UHFFFAOYSA-M benzyl(tributyl)azanium;chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CC1=CC=CC=C1 VJGNLOIQCWLBJR-UHFFFAOYSA-M 0.000 description 1
KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
USFRYJRPHFMVBZ-UHFFFAOYSA-M benzyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1=CC=CC=C1 USFRYJRPHFMVBZ-UHFFFAOYSA-M 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
239000001273 butane Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ZNFYPPCUDSCDPR-UHFFFAOYSA-M butyl(triethyl)azanium;bromide Chemical compound [Br-].CCCC[N+](CC)(CC)CC ZNFYPPCUDSCDPR-UHFFFAOYSA-M 0.000 description 1
IKWKJIWDLVYZIY-UHFFFAOYSA-M butyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCC)C1=CC=CC=C1 IKWKJIWDLVYZIY-UHFFFAOYSA-M 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical class NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
JHYNXXDQQHTCHJ-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 JHYNXXDQQHTCHJ-UHFFFAOYSA-M 0.000 description 1
SLAFUPJSGFVWPP-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 SLAFUPJSGFVWPP-UHFFFAOYSA-M 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 description 1
125000004492 methyl ester group Chemical group 0.000 description 1
QLPMKRZYJPNIRP-UHFFFAOYSA-M methyl(trioctyl)azanium;bromide Chemical compound [Br-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC QLPMKRZYJPNIRP-UHFFFAOYSA-M 0.000 description 1
LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 description 1
230000001035 methylating effect Effects 0.000 description 1
DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
150000002780 morpholines Chemical class 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000002891 organic anions Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
150000002899 organoaluminium compounds Chemical class 0.000 description 1
125000001979 organolithium group Chemical group 0.000 description 1
150000002901 organomagnesium compounds Chemical class 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
150000004714 phosphonium salts Chemical class 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
238000000926 separation method Methods 0.000 description 1
150000003354 serine derivatives Chemical class 0.000 description 1
229910001923 silver oxide Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
KBLZDCFTQSIIOH-UHFFFAOYSA-M tetrabutylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC KBLZDCFTQSIIOH-UHFFFAOYSA-M 0.000 description 1
RSHBFZCIFFBTEW-UHFFFAOYSA-M tetrabutylazanium;thiocyanate Chemical compound [S-]C#N.CCCC[N+](CCCC)(CCCC)CCCC RSHBFZCIFFBTEW-UHFFFAOYSA-M 0.000 description 1
HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
229940073455 tetraethylammonium hydroxide Drugs 0.000 description 1
UQFSVBXCNGCBBW-UHFFFAOYSA-M tetraethylammonium iodide Chemical compound [I-].CC[N+](CC)(CC)CC UQFSVBXCNGCBBW-UHFFFAOYSA-M 0.000 description 1
LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 1
RXMRGBVLCSYIBO-UHFFFAOYSA-M tetramethylazanium;iodide Chemical compound [I-].C[N+](C)(C)C RXMRGBVLCSYIBO-UHFFFAOYSA-M 0.000 description 1
QBVXKDJEZKEASM-UHFFFAOYSA-M tetraoctylammonium bromide Chemical compound [Br-].CCCCCCCC[N+](CCCCCCCC)(CCCCCCCC)CCCCCCCC QBVXKDJEZKEASM-UHFFFAOYSA-M 0.000 description 1
BRKFQVAOMSWFDU-UHFFFAOYSA-M tetraphenylphosphanium;bromide Chemical compound [Br-].C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 BRKFQVAOMSWFDU-UHFFFAOYSA-M 0.000 description 1
BGQMOFGZRJUORO-UHFFFAOYSA-M tetrapropylammonium bromide Chemical compound [Br-].CCC[N+](CCC)(CCC)CCC BGQMOFGZRJUORO-UHFFFAOYSA-M 0.000 description 1
LPSKDVINWQNWFE-UHFFFAOYSA-M tetrapropylazanium;hydroxide Chemical compound [OH-].CCC[N+](CCC)(CCC)CCC LPSKDVINWQNWFE-UHFFFAOYSA-M 0.000 description 1
IGVWFPZXBUTUCG-UHFFFAOYSA-M tetrapropylazanium;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.CCC[N+](CCC)(CCC)CCC IGVWFPZXBUTUCG-UHFFFAOYSA-M 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
MQAYPFVXSPHGJM-UHFFFAOYSA-M trimethyl(phenyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)C1=CC=CC=C1 MQAYPFVXSPHGJM-UHFFFAOYSA-M 0.000 description 1
LZOHWIXYBMRNAP-UHFFFAOYSA-M triphenyl(trityl)phosphanium;chloride Chemical compound [Cl-].C1=CC=CC=C1C([P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZOHWIXYBMRNAP-UHFFFAOYSA-M 0.000 description 1
JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1854—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/10—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MX2007001253A 2004-10-02 2005-09-30 Esquema de sintesis mejorado para lacosamida. MX2007001253A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04023556A EP1642889A1 (en)	2004-10-02	2004-10-02	Improved synthesis scheme for lacosamide
PCT/EP2005/010603 WO2006037574A1 (en)	2004-10-02	2005-09-30	Improved synthesis scheme for lacosamide

Publications (1)

Publication Number	Publication Date
MX2007001253A true MX2007001253A (es)	2008-10-02

Family

ID=34926827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2007001253A MX2007001253A (es)	2004-10-02	2005-09-30	Esquema de sintesis mejorado para lacosamida.

Country Status (24)

Country	Link
US (2)	US7884134B2 (uk)
EP (2)	EP1642889A1 (uk)
JP (1)	JP5128281B2 (uk)
KR (1)	KR101246169B1 (uk)
CN (2)	CN101928230B (uk)
AT (1)	ATE457975T1 (uk)
AU (1)	AU2005291456B2 (uk)
BR (1)	BRPI0516735B8 (uk)
CA (1)	CA2570598C (uk)
CY (1)	CY1109994T1 (uk)
DE (1)	DE602005019437D1 (uk)
DK (1)	DK1799635T3 (uk)
EA (1)	EA012588B1 (uk)
ES (1)	ES2341470T3 (uk)
HR (1)	HRP20100239T1 (uk)
IL (1)	IL180479A (uk)
MX (1)	MX2007001253A (uk)
NO (1)	NO336765B1 (uk)
NZ (1)	NZ552076A (uk)
PL (1)	PL1799635T3 (uk)
SI (1)	SI1799635T1 (uk)
UA (1)	UA95600C2 (uk)
WO (1)	WO2006037574A1 (uk)
ZA (1)	ZA200610000B (uk)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1243262B1 (en)	2001-03-20	2006-05-31	Schwarz Pharma Ag	Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
EP1243263B1 (en) *	2001-03-21	2002-11-27	Schwarz Pharma Ag	Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
EP1689378B1 (en) *	2003-12-02	2009-04-15	Schwarz Pharma Ag	Novel use of peptide compounds for treating central neuropathic pain
EP1579858A1 (en) *	2004-03-26	2005-09-28	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) *	2004-03-26	2010-10-07	Ucb Pharma Gmbh	Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) *	2004-03-26	2007-02-22	Srz Properties, Inc.	Combination therapy for pain in painful diabetic neuropathy
EA013591B1 (ru) *	2004-04-16	2010-06-30	Шварц Фарма Аг	Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd)
EP1604655A1 (en) *	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
PL1781276T3 (pl) *	2004-08-27	2010-11-30	Ucb Pharma Gmbh	Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (en) *	2004-10-02	2006-04-05	Schwarz Pharma Ag	Improved synthesis scheme for lacosamide
US20060252749A1 (en) *	2005-01-28	2006-11-09	Srz Properties, Inc.	Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) *	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) *	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
US8191500B2 (en)	2005-11-24	2012-06-05	Kronoplus Technical Ag	Coating device comprising flowing coating material for smooth or structured surfaces
CN101466390B (zh) *	2006-06-15	2014-03-12	优时比制药有限公司	用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) *	2006-06-30	2008-01-02	Schwarz Pharma Ag	Method for identifying CRMP modulators
AU2007260207B2 (en) *	2006-06-15	2012-11-08	Ucb Pharma Gmbh	Pharmaceutical composition with synergistic anticonvulsant effect
WO2009053070A1 (en) *	2007-10-23	2009-04-30	Schwarz Pharma Ag	Compounds for treating demyelination conditions
US8093426B2 (en)	2007-12-04	2012-01-10	Ranbaxy Laboratories Limited	Intermediate compounds and their use in preparation of lacosamide
US20090298947A1 (en)	2008-05-28	2009-12-03	Pliva Hrvatska D.O.O.	Polymorphic and amorphous forms of lacosamide and amorphous compositions
BRPI0921408B8 (pt) *	2008-11-07	2021-05-25	Ucb Pharma Gmbh	processo para a fabricação de (r)-2-acetamido-n-benzil-3-metoxipropion-amida (i) opticamente pura
DE102008059155A1 (de)	2008-11-27	2010-06-02	Ratiopharm Gmbh	Trockenverarbeitung und neue Formen von Lacosamid
CN101591300B (zh) *	2009-02-19	2011-05-04	成都伊诺达博医药科技有限公司	合成拉考沙胺的新方法
US20100240926A1 (en) *	2009-03-18	2010-09-23	Pliva Hrvatska D.O.O.	Process for preparing (r)-n-benzyl-2-(benyloxycarbonylamino)-3-methoxypropionamide
EP2462107A1 (en) *	2009-08-06	2012-06-13	Medichem, S.A.	Solid forms of an n-(phenylmethyl)propanamide derivative and processes of preparation
CN102020589B (zh) *	2009-09-19	2013-11-06	浙江九洲药业股份有限公司	一种氨基甲酸叔丁酯衍生物及其制备方法和应用
EP2480524A1 (en) *	2009-09-25	2012-08-01	Cadila Healthcare Limited	Processes for the preparation of lacosamide and intermediates thereof
US20130085304A1 (en)	2009-11-19	2013-04-04	Ranbaxy Laboratories Limited	Processes for preparation of polymorphic forms of lacosamide
WO2011092672A2 (en) *	2010-01-29	2011-08-04	Ranbaxy Laboratories Limited	Processes for reducing impurities in lacosamide
IT1398044B1 (it)	2010-01-29	2013-02-07	Archimica Srl	Processo per la preparazione della lacosamide
CN102146048B (zh) *	2010-02-06	2013-11-13	浙江九洲药业股份有限公司	拉科酰胺中间体化合物及其制备方法和应用
US8829226B2 (en)	2010-02-06	2014-09-09	Zhejiang Jiuzhou Pharmaceutical Co., Ltd	Lacosamide intermediate compound, preparation method thereof and use thereof
KR20120128667A (ko)	2010-02-08	2012-11-27	낫코 파마 리미티드	라코사미드의 제조방법
US8907132B2 (en)	2010-02-09	2014-12-09	Msn Laboratories Private Limited	Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide
WO2011130615A2 (en) *	2010-04-15	2011-10-20	Dr. Reddy's Laboratories Ltd.	Preparation of lacosamide
WO2011144983A2 (en)	2010-05-17	2011-11-24	Aurobindo Pharma Limited	An improved process for the preparation of lacosamide
EP2582833A1 (en)	2010-06-15	2013-04-24	Medichem, S.A.	Enzymatic resolution of racemic (2r,s)-2-(acetylamino)-3-methoxy-n-(phenylmethyl)propanamide
EP2399901A1 (en)	2010-06-23	2011-12-28	Archimica GmbH	Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide
US20130102811A1 (en) *	2010-07-02	2013-04-25	Sun Pharmaceutical Industries Ltd	Process for the preparation of lacosamide
US8957252B2 (en)	2010-07-27	2015-02-17	Indoco Remedies Limited	Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives
WO2012041986A1 (en)	2010-10-01	2012-04-05	Ucb Pharma Gmbh	Process for the preparation of amino acid derivatives
PL2444390T3 (pl)	2010-10-19	2017-06-30	Euticals Gmbh	Sposób wytwarzania Lakozamidu
EP2487152A1 (en)	2010-11-17	2012-08-15	UCB Pharma GmbH	Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine
GB201020026D0 (en)	2010-11-25	2011-01-12	Cambrex Karlskoga Ab	New process
EP2468261A1 (en)	2010-12-02	2012-06-27	UCB Pharma GmbH	Formulation of lacosamide
CN102320993B (zh) *	2011-07-13	2013-11-27	石家庄四药有限公司	一种制备(r)-2-叔丁氧羰基氨基-3-甲氧基丙酸的方法
WO2013024383A1 (en) *	2011-08-12	2013-02-21	Alembic Pharmaceuticals Limited	An improved process for the preparation of lacosamide
CA2847285C (en)	2011-08-29	2019-10-01	Signa S.A. De C.V.	Processes for the preparation of (r)-2-acetamido-n-benzyl-3-methoxypropionamide and intermediates thereof
WO2013072933A2 (en) *	2011-10-03	2013-05-23	Glenmark Generics Limited	Process for preparation of 2-acetamido-n-benzyl-3-methoxypropionamide
US9199916B2 (en)	2011-11-10	2015-12-01	Ramamohan Rao Davuluri	Process for the preparation of (R)-N-benzyl-2-acetamido-3-methoxypropionamide
JP2014533292A (ja)	2011-11-15	2014-12-11	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｎ−置換された２−（アセチルアミノ）−ｎ’−ベンジル−３−メトキシプロパンアミドの製造方法
US8748660B2 (en)	2012-07-09	2014-06-10	Council Of Scientific & Industrial Research	Process for the synthesis of antiepileptic drug lacosamide
CN102816083B (zh) *	2012-07-30	2015-09-23	永光制药有限公司	拉科酰胺的制备方法
GB201219627D0 (en)	2012-11-01	2012-12-12	Cambrex Karlskoga Ab	New process
WO2014155264A1 (en)	2013-03-25	2014-10-02	Jubilant Life Sciences Limited	Process for the preparation of lacosamide using novel intermediates
CN103342655A (zh) *	2013-07-02	2013-10-09	扬州大学	取代乙二酮双苯胺希夫碱合成取代酰胺的新方法
KR101578979B1 (ko)	2013-11-08	2015-12-18	에스티팜 주식회사	라코사마이드의 제조방법
WO2016030911A2 (en)	2014-08-28	2016-03-03	RAO, Davuluri Ramamohan	Improved process for the preparation of lacosamide and its novel intermediate
WO2016039393A1 (ja) *	2014-09-10	2016-03-17	株式会社エーピーアイコーポレーション	アミノ酸誘導体の製造方法
CN104761465B (zh) *	2015-03-18	2017-05-31	四川同晟生物医药有限公司	一种拉科酰胺的制备方法
CN106699605B (zh) *	2015-07-21	2019-08-20	上海医药集团股份有限公司	一种拉科酰胺中间体的甲基化方法
CN106699595B (zh) *	2015-07-21	2019-04-12	上海医药集团股份有限公司	一种拉科酰胺制备方法
IN2015CH05001A (uk)	2015-09-18	2015-10-16	Divis Lab Ltd
US10975117B2 (en)	2015-11-13	2021-04-13	Api Corporation	Method for producing lacosamide and intermediate thereof
AU2016381366A1 (en)	2015-12-30	2018-06-28	Adamas Pharmaceuticals, Inc.	Methods and compositions for the treatment of seizure-related disorders
US9718765B1 (en)	2016-06-21	2017-08-01	Sci Pharmtech, Inc.	Process for preparation of optically pure N-substituted-3-methoxypropionic acid derivatives
WO2018060781A1 (en) *	2016-09-28	2018-04-05	Unichem Laboratories Ltd	An improved process for the preparation of lacosamide
CN106811492B (zh) *	2017-01-18	2019-11-01	长兴制药股份有限公司	一种拉科酰胺的制备方法
KR20190081386A (ko)	2017-12-29	2019-07-09	강원대학교산학협력단	루핀아마이드를 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
KR20190081385A (ko)	2017-12-29	2019-07-09	강원대학교산학협력단	옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CN110320291A (zh) *	2019-06-21	2019-10-11	山东省药学科学院	一种hplc法定量检测拉考沙胺注射液含量的方法
JP2022072636A (ja) *	2020-10-30	2022-05-17	住友化学株式会社	アミド化合物の製造方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5129456A (en) *	1974-08-30	1976-03-12	Tanabe Seiyaku Co	Kogakukatsusei oo benjiruserinjudotai no seiho
JPS62132849A (ja) *	1985-12-04	1987-06-16	Toray Ind Inc	Ｄ−またはＬ−Ｎ−ｔ−ブトキシカルボニル−Ｏ−ベンジルセリンの製造方法
US5585358A (en)	1993-07-06	1996-12-17	Yissum Research Development Corporation Of The Hebrew University Of Jerusalem	Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
ATE202079T1 (de) *	1996-03-15	2001-06-15	Res Corp Technologies Inc	Krampflösende, enantiomere aminosäure-derivate
US6048899A (en) *	1997-03-17	2000-04-11	Research Corporation Tech., Inc.	Anticonvulsant enantiomeric amino acid derivatives
JP3996671B2 (ja) *	1997-07-09	2007-10-24	タマ化学工業株式会社	Ｎ−アルコキシカルボニル化、ｎ−アルケニルオキシカルボニル化またはｎ−アリールアルコキシカルボニル化されたアミノ酸類の製造方法
ATE301995T1 (de)	2000-08-17	2005-09-15	Teva Pharma	Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
EP1243262B1 (en)	2001-03-20	2006-05-31	Schwarz Pharma Ag	Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
EP1243263B1 (en)	2001-03-21	2002-11-27	Schwarz Pharma Ag	Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
ATE361289T1 (de) *	2002-08-05	2007-05-15	Lilly Co Eli	Piperazinsubstituierte arylbenzodiazepine
EP1689378B1 (en)	2003-12-02	2009-04-15	Schwarz Pharma Ag	Novel use of peptide compounds for treating central neuropathic pain
US20060009384A1 (en)	2003-12-05	2006-01-12	David Rudd	Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en)	2004-03-26	2007-02-22	Srz Properties, Inc.	Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en)	2004-03-26	2010-10-07	Ucb Pharma Gmbh	Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en)	2004-03-26	2005-09-28	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in painful diabetic neuropathy
EA013591B1 (ru)	2004-04-16	2010-06-30	Шварц Фарма Аг	Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd)
EP1604654A1 (en)	2004-05-18	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en)	2004-06-24	2008-09-23	Schwarz Pharma Ag	Method for treating tremor
PL1781276T3 (pl)	2004-08-27	2010-11-30	Ucb Pharma Gmbh	Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (en)	2004-10-02	2006-04-05	Schwarz Pharma Ag	Improved synthesis scheme for lacosamide
US20060252749A1 (en)	2005-01-28	2006-11-09	Srz Properties, Inc.	Lacosamide for add-on therapy of psychosis
EP1754476A1 (en)	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en)	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
US20070048372A1 (en)	2005-08-18	2007-03-01	Srz Properties, Inc.	Method for treating non-inflammatory osteoarthritic pain
CN101466390B (zh)	2006-06-15	2014-03-12	优时比制药有限公司	用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en)	2006-06-30	2008-01-02	Schwarz Pharma Ag	Method for identifying CRMP modulators
AU2007260207B2 (en)	2006-06-15	2012-11-08	Ucb Pharma Gmbh	Pharmaceutical composition with synergistic anticonvulsant effect
WO2009053070A1 (en)	2007-10-23	2009-04-30	Schwarz Pharma Ag	Compounds for treating demyelination conditions
EP2645997B1 (en)	2010-12-02	2022-08-10	UCB Pharma GmbH	Once daily formulation of lacosamide
EP2468261A1 (en)	2010-12-02	2012-06-27	UCB Pharma GmbH	Formulation of lacosamide

2004
- 2004-10-02 EP EP04023556A patent/EP1642889A1/en not_active Withdrawn
2005
- 2005-09-30 EP EP05794396A patent/EP1799635B1/en not_active Expired - Lifetime
- 2005-09-30 DK DK05794396.1T patent/DK1799635T3/da active
- 2005-09-30 MX MX2007001253A patent/MX2007001253A/es active IP Right Grant
- 2005-09-30 WO PCT/EP2005/010603 patent/WO2006037574A1/en not_active Ceased
- 2005-09-30 EA EA200700746A patent/EA012588B1/ru not_active IP Right Cessation
- 2005-09-30 CN CN2010101835217A patent/CN101928230B/zh not_active Expired - Fee Related
- 2005-09-30 JP JP2007533955A patent/JP5128281B2/ja not_active Expired - Lifetime
- 2005-09-30 BR BRPI0516735A patent/BRPI0516735B8/pt not_active IP Right Cessation
- 2005-09-30 NZ NZ552076A patent/NZ552076A/en not_active IP Right Cessation
- 2005-09-30 HR HR20100239T patent/HRP20100239T1/hr unknown
- 2005-09-30 CN CN2005800241755A patent/CN1989102B/zh not_active Expired - Fee Related
- 2005-09-30 AT AT05794396T patent/ATE457975T1/de active
- 2005-09-30 US US11/664,316 patent/US7884134B2/en not_active Expired - Fee Related
- 2005-09-30 KR KR1020077002247A patent/KR101246169B1/ko not_active Expired - Fee Related
- 2005-09-30 ES ES05794396T patent/ES2341470T3/es not_active Expired - Lifetime
- 2005-09-30 CA CA2570598A patent/CA2570598C/en not_active Expired - Fee Related
- 2005-09-30 PL PL05794396T patent/PL1799635T3/pl unknown
- 2005-09-30 DE DE602005019437T patent/DE602005019437D1/de not_active Expired - Lifetime
- 2005-09-30 SI SI200530992T patent/SI1799635T1/sl unknown
- 2005-09-30 UA UAA200704328A patent/UA95600C2/ru unknown
- 2005-09-30 AU AU2005291456A patent/AU2005291456B2/en not_active Ceased
2006
- 2006-11-30 ZA ZA200610000A patent/ZA200610000B/xx unknown
2007
- 2007-01-01 IL IL180479A patent/IL180479A/en active IP Right Grant
- 2007-04-30 NO NO20072250A patent/NO336765B1/no not_active IP Right Cessation
2010
- 2010-04-30 CY CY20101100383T patent/CY1109994T1/el unknown
- 2010-12-07 US US12/961,705 patent/US8809585B2/en active Active

Also Published As

Publication number	Publication date
WO2006037574A1 (en)	2006-04-13
CN1989102B (zh)	2011-04-20
ATE457975T1 (de)	2010-03-15
CN1989102A (zh)	2007-06-27
US8809585B2 (en)	2014-08-19
PL1799635T3 (pl)	2010-10-29
IL180479A (en)	2011-09-27
ZA200610000B (en)	2007-08-29
EP1799635A1 (en)	2007-06-27
HRP20100239T1 (hr)	2010-06-30
NZ552076A (en)	2010-09-30
CN101928230A (zh)	2010-12-29
KR20070057778A (ko)	2007-06-07
JP2008514669A (ja)	2008-05-08
DK1799635T3 (da)	2010-05-17
EP1642889A1 (en)	2006-04-05
US20080027137A1 (en)	2008-01-31
AU2005291456A1 (en)	2006-04-13
NO20072250L (no)	2007-04-30
US20110130350A1 (en)	2011-06-02
US7884134B2 (en)	2011-02-08
UA95600C2 (en)	2011-08-25
ES2341470T3 (es)	2010-06-21
CY1109994T1 (el)	2014-09-10
CA2570598A1 (en)	2006-04-13
IL180479A0 (en)	2007-06-03
NO336765B1 (no)	2015-10-26
EA200700746A1 (ru)	2007-08-31
BRPI0516735B8 (pt)	2021-05-25
KR101246169B1 (ko)	2013-03-21
SI1799635T1 (sl)	2010-06-30
EP1799635B1 (en)	2010-02-17
DE602005019437D1 (uk)	2010-04-01
BRPI0516735B1 (pt)	2021-01-12
CN101928230B (zh)	2012-11-07
BRPI0516735A (pt)	2008-09-23
JP5128281B2 (ja)	2013-01-23
EA012588B1 (ru)	2009-10-30
AU2005291456B2 (en)	2011-02-24
CA2570598C (en)	2013-12-17

Publication	Publication Date	Title
MX2007001253A (es)	2008-10-02	Esquema de sintesis mejorado para lacosamida.
JP2006521373A (ja)	2006-09-21	α−アミノカルボニル化合物の調製方法
KR101036536B1 (ko)	2011-05-24	(ｓ)-(+)-3-(아미노메틸)-5-메틸 헥산산의 합성
SG174886A1 (en)	2011-11-28	Method for obtaining optically pure amino acids
Yuste et al.	2000	Synthesis of enantiomerically pure 2-amino alcohols from amino acids mediated by sulfoxides
Tararov et al.	2002	An improved synthesis of enantiopure 2-azabicyclo [2.2. 1] heptane-3-carboxylic acid
Puglisi et al.	2008	Stereoselective nucleophilic addition to imines catalyzed by chiral bifunctional thiourea organocatalysts
Paradisi et al.	2001	A new stereocontrolled synthesis of uncommon tripeptides derived from 2, 6-diaminopimelic acid (2, 6-DAP)
US20020026081A1 (en)	2002-02-28	Process for producing alpha-aminoketone derivatives
JPH02256655A (ja)	1990-10-17	光学活性なスレオージヒドロキシフェニルセリン誘導体の製造方法
Fernández-Suárez et al.	1997	Asymmetric synthesis of the β-amino acid methyl ester derivative of onchidin:(2S, 3S)-methyl-3-amino-2-methyl-7-octynoate and its enantiomer
CA2184500A1 (en)	1995-09-28	Synthesis of compounds with predetermined chirality
EP1243576B1 (en)	2006-10-11	Processes for producing (aminomethyl)trifluoromethylcarbinol derivatives
EP1749816A1 (en)	2007-02-07	Production method of optically active diphenylalanine compounds
EP0225778A1 (en)	1987-06-16	Improved synthesis and purification of alpha-d-propoxyphene hydrochloride
Sekiguchi et al.	2008	Synthesis of enantiopure 2‐aryl‐2‐methoxypropionic acids and determination of their absolute configurations by X‐ray crystallography
Yonezawa et al.	1988	Dehydrooligopeptides. IX. Syntheses and conversions of. ALPHA.-dehydroglutamine derivatives to N-carboxy-. ALPHA.-dehydroglutamine anhydride and. DELTA. 1-dehydroglutaminyldipeptides.
KR0150566B1 (ko)	1998-10-15	광학활성이 있는 3-아미노 헤테로고리아민유도체의 제조방법
JPH11255742A (ja)	1999-09-21	光学活性ヒドロキシラクタム化合物の製造方法
JPWO2000055113A1 (ja)	2002-06-25	α−アミノケトン誘導体の製造方法
JPH0931058A (ja)	1997-02-04	４−ヒドロキシ−２−ピロリドンの製法

Legal Events

Date	Code	Title	Description
2010-07-15	FG	Grant or registration
2011-06-01	HC	Change of company name or juridical status